<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979130</url>
  </required_header>
  <id_info>
    <org_study_id>21-2774</org_study_id>
    <nct_id>NCT04979130</nct_id>
  </id_info>
  <brief_title>Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)</brief_title>
  <acronym>SIB</acronym>
  <official_title>A Randomized Parallel Comparison of Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about the effect of semaglutide once weekly on intestinal&#xD;
      permeability in individuals with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups</measure>
    <time_frame>Week 16 (visit 6)</time_frame>
    <description>The ratio of lactulose to mannitol will be measured in urine collected within 6 hours after ingestion of dual sugar. This ratio predominantly reflects small intestine permeability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in plasma LBP</measure>
    <time_frame>Week 8 (visit 4), Week 16 (visit 6)</time_frame>
    <description>Marker of intestinal permeability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in Serum zonulin</measure>
    <time_frame>Week 8 (visit 4), Week 16 (visit 6)</time_frame>
    <description>Marker of intestinal permeability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in Fecal Calprotectin</measure>
    <time_frame>Week 8 (visit 4), Week 16 (visit 6)</time_frame>
    <description>Marker of intestinal inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in plasma IL-6</measure>
    <time_frame>Week 8 (visit 4), Week 16 (visit 6)</time_frame>
    <description>Marker of chronic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in plasma IL-8</measure>
    <time_frame>Week 8 (visit 4), Week 16 (visit 6)</time_frame>
    <description>Marker of chronic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in plasma TNFα</measure>
    <time_frame>Week 8 (visit 4), Week 16 (visit 6)</time_frame>
    <description>Marker of chronic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in plasma hs-CRP</measure>
    <time_frame>Week 8 (visit 4), Week 16 (visit 6)</time_frame>
    <description>Marker of chronic inflammation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory: determine the effect of semaglutide as compared to placebo on intestinal microbiota in relation to changes in intestinal permeability and inflammatory markers</measure>
    <time_frame>Visit 6 (week 16)</time_frame>
    <description>Microbiome study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Chronic Inflammation</condition>
  <condition>Intestinal Permeability</condition>
  <arm_group>
    <arm_group_label>SC semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a once weekly, subcutaneous, Semaglutide injection for 16 weeks in addition to the participants background metformin monotherapy. The participants in this arm will begin at a 0.25 mg dose during the randomization visit, at week 4 this will be escalated to a 0.5 mg dose and at week 8 it will be escalated again to a 1.0 mg dose if tolerable by the participant. If the participant cannot tolerate the 0.25 mg dose at randomization or the 0.5 mg dose at week 4 they will be withdrawn from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will be given a once weekly, subcutaneous, placebo injection matching the Semaglutide experimental arm in addition to their background metformin monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.</description>
    <arm_group_label>SC semaglutide</arm_group_label>
    <other_name>Ozempic</other_name>
    <other_name>PDS290 pen-injector</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PDS290 pen-injector</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent obtained before any trial-related activities. Trial-related&#xD;
             activities are any procedures that are carried out as part of the trial, including&#xD;
             activities to determine suitability for the trial, except for protocol described&#xD;
             pre-screening activities, which require a separate informed consent.&#xD;
&#xD;
          2. Male or female, age above or equal to 18 years at the time of signing informed&#xD;
             consent.&#xD;
&#xD;
          3. Diagnosed with type 2 diabetes mellitus on metformin monotherapy&#xD;
&#xD;
          4. Hemoglobin A1c &lt;8.0% (&lt;64 mmol/mol) on screening day&#xD;
&#xD;
          5. Body mass index (BMI) 28-38 kg/m2&#xD;
&#xD;
          6. Low-grade inflammation, defined as elevated high sensitivity C-reactive protein (hs-&#xD;
             CRP &gt;2.0 and ≤10 mg/L). Impaired intestinal barrier function results in activation of&#xD;
             inflammatory pathway; therefore, excluding subjects with no evidence of inflammation&#xD;
             (hs-CRP ≤ 2 mg/L) will help to enrich our study population. Similar threshold for&#xD;
             hs-CRP as a marker of &quot;residual inflammatory risk&quot; (29) has been previously used as an&#xD;
             independent predictor of future vascular events (26, 30).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected hypersensitivity to trial product or related products.&#xD;
&#xD;
          2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-&#xD;
             bearing potential and not using a highly effective contraceptive method.&#xD;
&#xD;
          3. Participation in any clinical trial of an approved or non-approved investigational&#xD;
             medicinal product within 30 days before screening.&#xD;
&#xD;
          4. Any disorder, which in the investigator's opinion might jeopardize patient's safety or&#xD;
             compliance with the protocol.&#xD;
&#xD;
          5. Any of the following: myocardial infarction, stroke, hospitalization for unstable&#xD;
             angina pectoris or transient ischemic attack (TIA) within the past 60 days prior to&#xD;
             the day of screening.&#xD;
&#xD;
          6. Second anti-diabetic agent use within 3 months of screening.&#xD;
&#xD;
          7. Chronic kidney disease defined as eGFR &lt; 30 mL/min/1.73 m2.&#xD;
&#xD;
          8. C-reactive protein (hs-CRP &gt;10.0 mg/L) to eliminate patients with acute inflammatory&#xD;
             process at the time of screening.&#xD;
&#xD;
          9. Any recent infection or antibiotic use within 3 weeks&#xD;
&#xD;
         10. Regular use (more than a week duration) of anti-inflammatory medication (steroid or&#xD;
             NSAIDs) within 3 months of screening.&#xD;
&#xD;
         11. Regular use (more than a week duration) of any digestive health supplements, such as&#xD;
             probiotics or prebiotics within 3 months screening.&#xD;
&#xD;
         12. Diagnosis of chronic intestinal inflammatory disease such as Crohn's disease,&#xD;
             ulcerative colitis or irritable bowel syndrome.&#xD;
&#xD;
         13. Prior bariatric or bowel surgery&#xD;
&#xD;
         14. Heart failure presently classified as being in New York Heart Association (NYHA) Class&#xD;
             IV.&#xD;
&#xD;
         15. Presence or history of malignant neoplasm within 5 years prior to the day of&#xD;
             screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.&#xD;
&#xD;
         16. Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or medullary&#xD;
             thyroid carcinoma (MTC).&#xD;
&#xD;
         17. History of chronic pancreatitis or history of acute pancreatitis within 6 months of&#xD;
             screening.&#xD;
&#xD;
         18. Chronic consumption of &gt; 2 alcoholic standard drinks per day as defined by:&#xD;
&#xD;
               -  12 ounces of beer (5% alcohol content).&#xD;
&#xD;
               -  8 ounces of malt liquor (7% alcohol content).&#xD;
&#xD;
               -  5 ounces of wine (12% alcohol content).&#xD;
&#xD;
               -  1.5 ounces or a &quot;shot&quot; of 80-proof (40% alcohol content) distilled spirits or&#xD;
                  liquor (e.g., gin, rum, vodka, whiskey).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neda Rasouli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Onyiah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neda Rasouli, MD</last_name>
    <phone>303-724-4651</phone>
    <email>neda.rasouli@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carli Berghoff, BS</last_name>
    <phone>720-848-1816</phone>
    <email>carli.berghoff@cuanschutz.edu</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T2D</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>obesity</keyword>
  <keyword>intestinal permeability</keyword>
  <keyword>chronic inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

